MetaADEDB 2.0 @ LMMD
epalrestat
(CHNUOJQWGUIOLD-NFZZJPOKSA-N)
Structure
SMILES
C/C(=C\c1ccccc1)/C=C/1\SC(=S)N(C1=O)CC(=O)O
Type(s)
Investigational
Molecular Formula:
C15H13NO3S2
Molecular Weight:
319.399
Log P:
2.8566
Hydrogen Bond Acceptor:
6
Hydrogen Bond Donor:
1
TPSA:
115
CAS Number(s):
82159-09-9
Synonym(s)
1.
epalrestat
2.
3-carboxymethyl-5-(methyl-3-phenylpropenylidene)rhodanine
3.
ONO 2
4.
ONO 2235
5.
ONO-2
6.
ONO-2235
External Link(s)
MeSHC038131
PubChem Compound1549120
BindingDB50049730
ChEBI31539
CHEMBLCHEMBL56337
DrugBankDB15293
DrugCentral1021
KEGGdr:D01688
Therapeutic Target DatabaseD0T6NN
D03KOZ
ZINC1533688
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Acid refluxOFFSIDES
2Acute myocardial infarctionOFFSIDES
3Alanine Aminotransferase IncreasedOFFSIDES
4Alcohol consumptionOFFSIDES
5Alcohol poisoningOFFSIDES
6Altered state of consciousnessOFFSIDES
7AnorexiaOFFSIDES
8Anti-insulin antibody positiveOFFSIDES
9ApathyOFFSIDES
10AscitesOFFSIDES
11AsthenopiaOFFSIDES
12BalanitisOFFSIDES
13Band neutrophil percentage increasedOFFSIDES
14Bilirubin conjugated increasedOFFSIDES
15Bladder tamponadeOFFSIDES
16Blood albumin decreasedOFFSIDES
17Blood alkaline phosphatase increasedOFFSIDES
18Blood chloride increasedOFFSIDES
19Blood creatine phosphokinase increasedOFFSIDES
20Blood creatinine increasedOFFSIDES
21Blood glucose decreasedOFFSIDES
22Blood glucose fluctuationOFFSIDES
23Blood immunoglobulin EOFFSIDES
24Blood lactate dehydrogenase increasedOFFSIDES
25Blood potassium increasedOFFSIDES
26Blood pressure inadequately controlledOFFSIDES
27Blood urea increasedOFFSIDES
28Body TemperatureOFFSIDES
29CYTOMEGALOVIRUS ANTIGENOFFSIDES
30CellulitisOFFSIDES
31Chemical and Drug Induced Liver Injury28204799CTD
32CholangiolitisOFFSIDES
33Cytomegalovirus test positiveOFFSIDES
34DehydrationOFFSIDES
35Depressed Level of ConsciousnessOFFSIDES
36Depressed moodOFFSIDES
37Diabetes mellitus inadequate controlOFFSIDES
38Diabetic Autonomic NeuropathyOFFSIDES
39Diabetic NephropathyOFFSIDES
40Diabetic Neuropathies11353731
28204799		CTD
41Disease ProgressionOFFSIDES
42Disseminated Intravascular CoagulationOFFSIDES
43DyslaliaOFFSIDES
44Dysthymic DisorderOFFSIDES
45Echocardiogram abnormalOFFSIDES
46ErythemaOFFSIDES
47ExcoriationOFFSIDES
48Eye painOFFSIDES
49Eyelid DiseasesOFFSIDES
50Feeling abnormalOFFSIDES
51Gamma-Glutamyltransferase IncreasedOFFSIDES
52Gastric ulcerOFFSIDES
53Genital HerpesOFFSIDES
54Hypoaesthesia facialOFFSIDES
55HypophagiaOFFSIDES
56Hypopharyngeal CancerOFFSIDES
57Intra-aortic balloon placementOFFSIDES
58Lip erosionOFFSIDES
59Liver Cirrhosis28204799CTD
60Lymph node palpableOFFSIDES
61Lymphocyte count decreasedOFFSIDES
62Lymphocyte percentage decreasedOFFSIDES
63Lymphocyte stimulation test negativeOFFSIDES
64Lymphocyte stimulation test positiveOFFSIDES
65Mechanical ventilationOFFSIDES
66Metabolic acidosisOFFSIDES
67Multiple drug overdoseOFFSIDES
68Nephrotic SyndromeOFFSIDES
69Neutrophil count decreasedOFFSIDES
70Oculomucocutaneous syndromeOFFSIDES
71OliguriaOFFSIDES
72PROTHROMBIN TIMEOFFSIDES
73Percutaneous Coronary InterventionOFFSIDES
74Protein total decreasedOFFSIDES
75ScabOFFSIDES
76Sick Sinus SyndromeOFFSIDES
77Stevens-Johnson SyndromeOFFSIDES
78Surgical vascular shuntOFFSIDES
79Transaminases increasedOFFSIDES
80Urine osmolarity increasedOFFSIDES
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120238

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.